}

FDA alert on confusing labels on compounded products

10/10/2018

The FDA has received reports of dosing errors and confusion caused by differing labeling practices between conventional manufacturers and compounders. Because labels of compounded products are not reviewed by FDA prior to marketing, FDA is reminding healthcare professionals to be vigilant when administering compounded products to patients to avoid confusion and ensure that each patient is administered the prescribed dose of the intended drug.  See the FDA safety alert.

<< return to Advocacy Updates